MRDS psychosis
Conditions
Interventions
On two occasions non- invasive 3.0 Tesla MRI recordings will be conducted
following a single dose of 4 mg biperiden or placebo, administered orally. For
the SPECT study a registered, well- validated
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with first-episode psychosis as defined by the standardised criteria of the CASH -Medication free -Duration of untreated psychosis no more than 1 year. -18 years and older
Exclusion criteria
Exclusion criteria: -Use of antipsychotics and anticholinergics -Contraindications for MRI -Severe neurological, endocrine or psychiatric disorders -Pregnancy -Current use of recreational drugs; participants must be abstinent of recreational drugs such as cannabis at least 4 weaks prior to participation. -Tardive dyskinesia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -M1 receptor binding: ROI*s will be the hippocampus and the dorsolateral prefrontal cortex. | — |
Secondary
| Measure | Time frame |
|---|---|
| -BOLD signal activation during cognitive tasks PAL (40) and ER -40 (62) under cholinergic challenge and in placebo. (ROI*s DLPFC and the hippocampus). -Neuropsychological tests: CANTAB battery for schizophrenia. Additional study parameters: -DTI, RSfMRI, MRS -(Epi)genetics | — |
Countries
Netherlands
Outcome results
None listed